Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting

Salix Pharmaceuticals, Inc. today announced that the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2010) will be an important venue for ongoing discussion of hepatic encephalopathy, or HE.

1 Nov 2010

FDA new approvals, antibiotic and neurological drugs

Two new drugs have gained approval from the US Food and Drug Administration (FDA) – one is an antibiotic from Forest Labs and the other a first-time treatment for a neurological disorder developed by Avanir Pharmaceuticals. Another waiting for approval is Biodel's fast-acting insulin Linjeta. On the other hand seven new drugs got rejected including a diabetes drug from Amylin Pharmaceuticals and weight-loss drugs from Arena Pharmaceuticals and Vivus, respectively.

31 Oct 2010

Surrogates preference increases for value-laden decisions in ICUs: Report

The decision to stop life-support for incapacitated and critically ill patients is, for surrogate decision makers, often fraught with moral and ethical uncertainty, and long-term emotional consequences. But as difficult as these decisions are, more than half of surrogate decision makers prefer to have full authority over the choice than to share or cede that power to physicians, according to a recent study out of the University of Pittsburgh School of Medicine.

30 Oct 2010

New findings on protein factories could unravel cell complexities, lead to new antibiotics and disease treatments

A team from The Scripps Research Institute has revealed the first-ever pictures of the formation of cells' "protein factories." In addition to being a major technical feat on its own, the work could open new pathways for development of antibiotics and treatments for diseases tied to errors in ribosome formation. In addition, the techniques developed in the study can now be applied to other complex challenges in the understanding of cellular processes.

30 Oct 2010

Teflaro receives FDA approval for treatment of bacterial infections

The U.S. Food and Drug Administration today approved Teflaro (ceftaroline fosamil), an injectable antibiotic to treat adults with community acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), including methicillin-resistant Staphylococcus aureus (MRSA).

30 Oct 2010

North American children may be 'too clean'

Rising levels of allergic asthma and eczema in North American children have Canadian scientists wondering if there is such a thing as being "too clean." "We see auto-immune diseases like asthma and eczema increasing rapidly in North American children, but we don't see the same effect in children in the developing world," says Dr. B. Brett Finlay, a Professor in the Michael Smith Laboratories at the University of British Columbia.

29 Oct 2010

Viropharma 2010 third quarter net sales increases 46% to $317.4 million

ViroPharma Incorporated reported today its financial results for the third quarter ended September 30, 2010.

27 Oct 2010

MDI and Westburg enter exclusive distribution agreement for Detect-Ready MRSA panel in Benelux region

Molecular Detection Inc. (MDI), a company developing Detect-Ready™ tests designed to increase the speed and accuracy of infectious disease diagnosis, and life sciences and diagnostics distributor Westburg BV today announced that they have entered into an exclusive agreement for distribution of MDI's Detect-Ready MRSA panel in the Benelux region.

26 Oct 2010

Researchers find new antibiotic strategies for hibernating bugs

New strategies to apply antibiotics more effectively to hibernating bugs have been developed by researchers at the University of Hertfordshire.

26 Oct 2010

Knowledge gaps and unjustified fear common among caregivers of children with MRSA

Knowledge gaps and fear - some of it unjustified - are common among the caregivers of children with a drug-resistant staph bacterium known as MRSA, according to the results of a small study from the Johns Hopkins Children Center. These caregivers thirst for timely, detailed and simple information, the researchers add.

26 Oct 2010

Dietary intake of PUFAs associated with decreased prevalence of periodontitis

Periodontitis, a common inflammatory disease in which gum tissue separates from teeth, leads to accumulation of bacteria and potential bone and tooth loss. Although traditional treatments concentrate on the bacterial infection, more recent strategies target the inflammatory response.

26 Oct 2010

Haiti cholera epidemic abates

The rate of deaths in Haiti's cholera epidemic slowed on Monday. This followed a multinational medical operation scale up to limit the spread of an outbreak that has killed 259 people in the earthquake-hit country. However Haitian and international health authorities are still bracing for more cases before the epidemic is finally controlled. So far, the epidemic has mostly impacted two rural central Haitian provinces, Artibonite and Center, along with the few isolated cases in the capital Port-au-Prince. Suspected cases have also been reported in the Nord and Sud provinces.

25 Oct 2010

Enrollment complete in ViroPharma's Phase 2 study evaluating subcutaneous delivery of Cinryze

ViroPharma Incorporated today announced that it has completed enrollment in its Phase 2 study evaluating subcutaneous delivery of Cinryze™ (C1esterase inhibitor [human]). This multi-center, open-label, multi-dose Phase 2 study is designed to evaluate the safety, pharmacokinetics and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze in adolescent and adult subjects with hereditary angioedema (HAE).

25 Oct 2010

NovaBay delivers two poster presentations on Aganocide compounds at IDSA Annual Meeting

NovaBay Pharmaceuticals, Inc. a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, delivered two poster presentations on its compounds at the 48th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Vancouver, Canada.

25 Oct 2010

Intercell's IC43 Phase II trial against Pseudomonas aeruginosa infections meets primary endpoint

Intercell AG today announced results from a Phase II clinical trial involving the company's investigational nosocomial vaccine candidate (IC43) against infections with the bacterium Pseudomonas aeruginosa, a leading cause of hospital-acquired infections with increasing antibiotic resistance and hence a very high unmet medical need.

25 Oct 2010

Incidence of KPC-producing bacteria is rising in Chicago

In a survey of Chicago-area healthcare facilities, researchers at Rush University Medical Center and the Cook County Department of Public Health have found that the incidence of KPC-producing bacteria is rising. These bugs cause infections with high mortality rates and are resistant to the most commonly used antibiotics.

25 Oct 2010

UCLA researchers receive grant to develop medical products against radiation exposure

Researchers in the Radiation Oncology Department at UCLA's Jonsson Comprehensive Cancer Center have received a $14 million grant to develop countermeasures that will help treat damage caused by radiological or nuclear threats such as a dirty bomb attack.

25 Oct 2010

Vancomycin beneficial for managing patients hospitalized with cellulits

Patients admitted to the hospital for the common bacterial skin infection cellulitis should be treated as a first line of defense with the potent antibiotic drug vancomycin rather than other antibiotics such as penicillin, according to a Henry Ford Hospital study.

25 Oct 2010

Maven Semantic updates Antiviral research database

Maven Semantic announces updates to their Antiviral research database. The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector.

25 Oct 2010

Optimer presents two fidaxomicin Phase 3 trials data for CDI infection at IDSA Annual Meeting

Optimer Pharmaceuticals, Inc. announced today the presentation of combined data from its two fidaxomicin Phase 3 trials in patients with Clostridium difficile infection (CDI) at the 48th Annual Meeting of the Infectious Disease Society of America (IDSA) in Vancouver, British Columbia, Canada.

25 Oct 2010

Antibiotic News and Research

Further Reading

Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting

FDA new approvals, antibiotic and neurological drugs

Surrogates preference increases for value-laden decisions in ICUs: Report

New findings on protein factories could unravel cell complexities, lead to new antibiotics and disease treatments

Teflaro receives FDA approval for treatment of bacterial infections

North American children may be 'too clean'

Viropharma 2010 third quarter net sales increases 46% to $317.4 million

MDI and Westburg enter exclusive distribution agreement for Detect-Ready MRSA panel in Benelux region

Researchers find new antibiotic strategies for hibernating bugs

Knowledge gaps and unjustified fear common among caregivers of children with MRSA

Dietary intake of PUFAs associated with decreased prevalence of periodontitis

Haiti cholera epidemic abates

Enrollment complete in ViroPharma's Phase 2 study evaluating subcutaneous delivery of Cinryze

NovaBay delivers two poster presentations on Aganocide compounds at IDSA Annual Meeting

Intercell's IC43 Phase II trial against Pseudomonas aeruginosa infections meets primary endpoint

Incidence of KPC-producing bacteria is rising in Chicago

UCLA researchers receive grant to develop medical products against radiation exposure

Vancomycin beneficial for managing patients hospitalized with cellulits

Maven Semantic updates Antiviral research database

Optimer presents two fidaxomicin Phase 3 trials data for CDI infection at IDSA Annual Meeting

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News